A Proof Of Concept Study To Evaluate Tiotropium as Add-on Therapy to Inhaled Budesonide/Formoterol Combination in COPD
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Change in trough FEV1 for tiotropium compared to placebo when added to formoterol/budesonide combination
研究概览
简要总结
Different medications are often used in combination for the condition COPD (chronic obstructive pulmonary disease). Some medicines act by opening the airways (bronchodilators) and some act as anti-inflammatories (steroids). More recently an approach of using a combination inhaler (containing a steroid and a long-acting bronchodilator) at the same time as a long acting bronchodilator of a different group of medicines (anti-cholinergics inhalers) has been used. This approach is sometimes called 'triple therapy'. Studies which have looked at these combinations usually use only standard blowing tests (spirometry) to test these medicines and focus on the effects of the medicines at their highest (peak) levels. It is some ways more relevant to study these medicines towards to end of the dose period (trough)- just before the next dose. This is when there is less medicine in the system, and differences in drug effects are more obvious. There are also more detailed breathing tests than spirometry which get a more detailed picture of the way the lungs respond to bronchodilator medicines. The investigators have studied 'triple therapy' in COPD, by measuring the effects at the end of the dosing interval (trough) using a range of detailed respiratory tests.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Current or ex-smokers
- •aged over 50years
- •FEV1/FVC ratio less than 0.7
- •FEV1 less than 60% predicted
排除标准
- •Diagnosis of asthma, ABPA or bronchiectasis
- •Recent RTI or steroid use
- •Inability to perform study procedures or to give informed consent
- •Known sensitivity to trial medications
研究组 & 干预措施
Triple therapy
Symbicort and tiotropium
干预措施: Budesonide/formoterol and tiotropium (Drug)
Combination therapy
Symbicort and placebo
干预措施: Budesonide/formoterol and placebo (Drug)
结局指标
主要结局
Change in trough FEV1 for tiotropium compared to placebo when added to formoterol/budesonide combination
时间窗: 2 weeks
次要结局
- Change in IOS and bodyplethysmography at trough for tiotropium compared to placebo when added to formoterol/budesonide combination(2 weeks)
- Change in spirometry, IOS and Bodyplethysmography at trough for formoterol/budesonide compared to washed-out baseline(4 weeks)
研究者
Brian J Lipworth
Professor (Clinical) Airway allergy and COPD
University of Dundee
